Biological perspectives: Psychiatric drug-drug interactions: A review

Perspectives in Psychiatric Care

Volumn 46, Issue 3, 2010, Pages 244-251

  Keltner, Norman L ^a   Moore, Randy L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P; PSYCHOTROPIC AGENT;

ARTICLE; BLOOD; DRUG INTERACTION; ENZYME SPECIFICITY; HUMAN; MENTAL DISEASE; PHARMACOKINETICS; PHYSIOLOGY;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; P-GLYCOPROTEINS; PHARMACOKINETICS; PSYCHOTROPIC DRUGS; SUBSTRATE SPECIFICITY;

EID: 77955066892     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2010.00267.x     Document Type: Article

References (18)

1. Antai-Otong D. Adverse drug reactions associated with antipsychotics, antidepressants, and mood stabilizers. Nursing Clinics of North America 2003, 38:161-176. doi: 10.1016/S0029-6465(02)00069-5
2. Bauer M, Karch R, Neumann F, Abrahim A, Wagner C, Kletter K, Langer O. Age dependency of cerebral P-gp function. European Journal of Clinical Pharmacology 2009, 65:941-946. doi: 10.1007/s00228-009-0709-5
3. Cozza K L, Armstrong S C. The cytochrome P450 system 2001, Washington, DC, American Psychiatric Publishing, Inc
4. Cozza K L, Armstrong S C, Oesterheld J R. Drug interaction: Principles for medical practice 2003, 2nd, ed., Washington, DC, American Psychiatric Publishing, Inc
5. Guengerich F P. Role of cytochrome P450 enzymes in drug-drug interactions. Advances in Pharmacology 1997, 43:7-35.
6. Izzo A A, Ernst E. Interactions between herbal medicines and prescribed drugs, an updated systematic review. Drugs 2009, 69(13):1777-1798. doi: 4[pii]10.2165/11317010-000000000-00000
7. Katzung B G. Basic and clinical pharmacology 2007, 10th, ed., New York, McGraw Hill & Lange
8. Keltner N L, Folks D G. Psychotropic drugs 2005, 4th, ed., St. Louis, MO, Elsevier
9. Keltner N L, Schwecke L H, Bostrom C E. Psychiatric nursing 2007, 5th, ed., St. Louis, MO, Elsevier
10. Kharasch E D, Walker A, Whittington D, Hoffer C, Bedynek P S. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug and Alcohol Dependence 2009, 101:158-168. doi: S0376-8716(09)00013-1[pii]10.1016/j.drugalcdep.2008.12.009
11. Lehne R A. Pharmacology for nursing care 2007, St. Louis, MO, Saunders & Elsevier
12. Marchetti S, Mazzanti R, Beijnen J H, Schellens J H M. Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007, 12:927-941. doi: 12/8/927 [pii]10.1634/theoncologist.12-8-927
13. Preskorn S H. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). Journal of Psychiatric Practice 2003, 9(3):228-236. doi: 00131746-200305000-00006[pii
14. Sandson N B, Armstrong S C, Cozza K L. An overview of psychotropic drug-drug interactions. Psychosomatics 2005, 44:464-494. doi: 46/5/464[pii]10.1176/appi.psy.46.5.464
15. Strack D, Leckband S, Meyer J. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. Journal of Psychiatric Practice 2009, 15(6):442-448. doi: 10.1097/01.pra.0000364285.55586.ad00131746-200911000-00003[pii
16. Milk thistle. 2009, http://www.umm.edu/altmed/articles/milk-thistle-000266.htm, University of Maryland Medical Center, Retrieved March 16, 2010, from
17. Varma M V S, Ashokraj Y, Dey C S, Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacological Research 2003, 48:347-359. doi: 10.1016/S1043-6618(03)00158-0
18. Wu J-W, Lin L-C, Tsai T-H. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. Journal of Ethnopharmacology 2009, 121:185-193. doi: S03788741(08)00621-1[pii]10.1016/j.jep.2008.10.036